Disputes have always arisen over the classification of marijuana as a Schedule I substance. The federal level still prohibits the use of cannabis. However, 37 states have made the use of medical marijuana legal, and 23 have legalized the use for
recreational purposes.
In 2023, the HHS advised the rescheduling of marijuana to Schedule III which will decrease penalties on those who possess or use marijuana, and allow increased medical research on its effect. However, this change wouldn’t necessarily legalize marijuana nationwide.
Another challenge is the ability to control new synthetic drugs including new
synthetic benzodiazepines which again do not belong to any specific category. These drugs are intended to produce similar effects as controlled substances but they nearly always come with a different chemical formula which makes them difficult to control.
Many experts argue that drug scheduling is ineffective and presupposes an outdated system. For instance, substances such as psilocybin (magic mushrooms) remain Schedule I even if the data on their effectiveness in treating PTSD and depression are becoming more and more numerous.
The opioid crisis also still influences the evolution of the rule surrounding Schedule II opioids’ prescription and management. At the same time, regulators should not let their guard down regarding synthetic drugs and new chemical substances which the system faces even today. The future of new drug scheduling will also rely on the changes in public opinion and scientific research.